Lakefront Biotherapeutics (GLPGF) Stock Price & Analysis
Lakefront Biotherapeutics (GLPGF) — price $35.15 (0.00%), as of the Nov 19, 2026 trading session; market cap $2.32B.
Educational signal · not a buy or sell recommendation · How to read this
Lakefront Biotherapeutics · GLPGF
Galapagos N.V. is an integrated biopharmaceutical company headquartered in Belgium, dedicated to discovering, developing, and commercializing innovative medicines for high unmet medical needs. The company maintains a robust pipeline of drug candidates targeting various inflammatory, fibrotic, and kidney diseases, supported by strategic collaborations with global pharmaceutical leaders.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $35.15 | |
| Change on the day | 0.00% | |
| 52-week range | $26.24 – $35.15 | |
| Market capitalisation | $2.32B | |
| Price / earnings (trailing) | 4.26 | |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for Lakefront Biotherapeutics (GLPGF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Lakefront Biotherapeutics (GLPGF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Lakefront Biotherapeutics (GLPGF) is the company analyzed here. It employs 452 people and is led by Henry Gosebruch. In Q3 FY2026 it reported revenue of €7M and net income of -€3M. The market values it at $2.32B.
What do the latest results show for Lakefront Biotherapeutics (GLPGF)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of €7M. Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | €7M | -€3M | -€0.04 (diluted) |
| Q2 FY2026 | €12M | €2M | €0.03 (diluted) |
| Q1 FY2026 | €7M | €15M | €0.21 (diluted) |
| Q4 FY2025 | €900M | €782M | €11.86 (diluted) |
What are the financial strengths and risks for Lakefront Biotherapeutics (GLPGF)?
Short answer · as of
The distress and quality screens read Altman Z 21.91 · Piotroski F 4. Trailing ratios: ROE 16.9% · ROA 14.5% · current ratio 30.48 · earnings yield 23.8% · free-cash-flow yield -14.7%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GLPGF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported GLPGF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Common Questions About GLPGF
These answers are editorial: 1 of these 8 answers is drawn from the GLPGF research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is GLPGF a good stock to buy?
Stock Expert AI does not rate GLPGF buy, sell or hold. Lakefront Biotherapeutics has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the GLPGF stock price today?
The last price recorded for Lakefront Biotherapeutics (GLPGF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for GLPGF, particularly regarding its pipeline?
The primary risks for GLPGF are inherently tied to the high-risk nature of biopharmaceutical development. A significant concern is the potential for clinical trial failures, where drug candidates may not demonstrate sufficient efficacy or safety, leading to program termination and substantial financial losses.
What are the key factors to evaluate for GLPGF?
Evaluate GLPGF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Galapagos N.V. has established strategic collaboration agreements with major pharmaceutical companies including Gilead Sciences, Inc., AbbVie S.à r.l., and Novartis Pharma AG, enhancing its development capabilities and market reach. Not financial advice.
How frequently does GLPGF data refresh on this page?
GLPGF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven GLPGF's recent stock price performance?
Lakefront Biotherapeutics (GLPGF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse and active clinical pipeline targeting multiple high unmet medical needs across inflammatory, fibrotic, and kidney diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GLPGF overvalued or undervalued right now?
The trailing P/E of Lakefront Biotherapeutics (GLPGF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research GLPGF before investing?
Before investing in Lakefront Biotherapeutics (GLPGF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 9 from Financial Modeling Prep (FMP) and 6 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com